Prostate cancer (PCa) is the fourth most frequently diagnosed cancer worldwide, accounting for 7.3% of all cancers. PCa mortality is the fifth most common cause of cancer death. Despite well-known factors influencing the development of PCa, such as age, race/ethnicity and family history, many researchers have raised the possibility of persistent infections with oncogenic viruses. Therefore, we aimed to assess the frequency of Epstein–Barr virus (EBV) DNA in tissue collected from PCa patients. Next, the frequency and the level of Epstein–Barr virus capsid antigen (EBVCA) and Epstein–Barr nuclear antigen 1 (EBNA1) antibodies in both IgA and IgG classes were measured. The antibody titer was also analyzed depending on the risk group, Gleason score (GS) and tumor, node, metastasis (TNM) classification. Serum samples were analyzed using the Microblot-Array EBV IgM, IgA and IgG test kits. The study group consisted of 115 patients diagnosed and histopathologically confirmed with PCa. In 49% of patients included in the study, EBV DNA was detected in the tumor tissue. The studies showed both higher seroprevalence and higher antibody titers in patients with EBV-positive PCa compared to patients with EBV-negative PCa. We also observed a dependence of antibody titer on pathological features, such as GS, risk group and T stage.
前列腺癌（PCa）是全球第四大常见确诊癌症，占所有癌症病例的7.3%。其死亡率位列癌症致死原因的第五位。尽管年龄、种族/民族及家族史等影响前列腺癌发展的因素已较为明确，但许多研究者提出致癌病毒的持续感染可能与之相关。因此，本研究旨在评估前列腺癌患者组织中EB病毒（EBV）DNA的检出频率，进而检测EB病毒衣壳抗原（EBVCA）和EB病毒核抗原1（EBNA1）的IgA与IgG类抗体阳性率及水平，并依据风险分级、格里森评分（GS）及TNM分期分析抗体滴度的变化规律。研究采用微斑点阵列EBV IgM/IgA/IgG检测试剂盒对血清样本进行分析，纳入115例经病理确诊的前列腺癌患者。结果显示，49%的患者肿瘤组织中检出EBV DNA。与EBV阴性前列腺癌患者相比，EBV阳性患者血清阳性率及抗体滴度均显著升高。同时研究发现抗体滴度与格里森评分、风险分级及T分期等病理特征存在相关性。
Can the Epstein–Barr Virus Play a Role in the Development of Prostate Cancer?
肿瘤(癌症)患者之家